

Wolfgang Stremmel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6484532/publications.pdf>

Version: 2024-02-01

168
papers

7,498
citations

61984

43
h-index

58581

82
g-index

176
all docs

176
docs citations

176
times ranked

7527
citing authors

#	ARTICLE	IF	CITATIONS
1	Letter to the editor regarding “Dietary bovine milk miRNAs transported in extracellular vesicles are partially stable during GI digestion, are bioavailable and reach target tissues but need a minimum dose to impact on gene expression” European Journal of Nutrition, 2022, 61, 1695-1696.	3.9	2
2	Role of fatty acid transport protein 4 in metabolic tissues: insights into obesity and fatty liver disease. Bioscience Reports, 2022, 42, .	2.4	12
3	Delayed-Release Phosphatidylcholine Is Effective for Treatment of Ulcerative Colitis: A Meta-Analysis. Digestive Diseases, 2021, 39, 508-515.	1.9	16
4	Elevation of autoantibodies to cerebral proteins in hepatic encephalopathy: Another pathogenic factor?. Digestive Diseases, 2021, , .	1.9	2
5	The neglected biliary mucus and its phosphatidylcholine content: a putative player in pathogenesis of primary cholangitis—a narrative review article. Annals of Translational Medicine, 2021, 9, 738-738.	1.7	2
6	Exosome-Derived MicroRNAs of Human Milk and Their Effects on Infant Health and Development. Biomolecules, 2021, 11, 851.	4.0	66
7	Methionine and Choline Deficient Diet Enhances Adipose Lipolysis and Leptin Release in <i>Ap2^{Cre} Fatp4</i> Knockout Mice. Molecular Nutrition and Food Research, 2020, 64, e2000361.	3.3	5
8	Plasma Lipidome, PNPLA3 polymorphism and hepatic steatosis in hereditary hemochromatosis. BMC Gastroenterology, 2020, 20, 230.	2.0	7
9	Milk Exosomes Prevent Intestinal Inflammation in a Genetic Mouse Model of Ulcerative Colitis: A Pilot Experiment. Inflammatory Intestinal Diseases, 2020, 5, 117-123.	1.9	45
10	Coagulation Parameters in Wilson Disease. Journal of Gastrointestinal and Liver Diseases, 2020, 24, 183-188.	0.9	5
11	Real-World Outcomes of Vedolizumab Therapy in Ulcerative Colitis and Crohn’s Disease at a Tertiary Referral Center. Digestive Diseases, 2019, 37, 33-44.	1.9	12
12	The Bile Acid-Phospholipid Conjugate Ursodeoxycholy-Lysophosphatidylethanolamide (UDCA-LPE) Disintegrates the Lipid Backbone of Raft Plasma Membrane Domains by the Removal of the Membrane Phospholipase A2. International Journal of Molecular Sciences, 2019, 20, 5631.	4.1	1
13	Association between serum IgG level and clinical course in primary sclerosing cholangitis. BMC Gastroenterology, 2019, 19, 153.	2.0	4
14	Phosphatidylcholine Passes by Paracellular Transport to the Apical Side of the Polarized Biliary Tumor Cell Line Mz-ChA-1. International Journal of Molecular Sciences, 2019, 20, 4034.	4.1	5
15	Hepatic Encephalopathy Aggravated by Systemic Inflammation. Digestive Diseases, 2019, 37, 509-517.	1.9	12
16	An alternative membrane topology permits lipid droplet localization of peroxisomal fatty acyl-CoA reductase 1. Journal of Cell Science, 2019, 132, .	2.0	15
17	Critical Role of Hepatic Fatty-Acyl Phospholipid Remodeling in Obese and Nonobese Fatty Liver Mouse Models. , 2019, , 239-256.		0
18	Shear-Enhanced Dynamic Adhesion of Lactobacillus rhamnosus GG on Intestinal Epithelia: Correlative Effect of Protein Expression and Interface Mechanics. Langmuir, 2019, 35, 529-537.	3.5	9

#	ARTICLE	IF	CITATIONS
19	Elevation of blood lipids in hepatocyte-specific fatty acid transport 4-deficient mice fed with high glucose diets. <i>Molecular Genetics and Metabolism</i> , 2019, 126, 30-38.	1.1	5
20	Clinical features of Wilson disease. <i>Annals of Translational Medicine</i> , 2019, 7, S61-S61.	1.7	21
21	Editorial for focused issue "Wilson Disease: From Genetics to Management of Disease". <i>Annals of Translational Medicine</i> , 2019, 7, S55-S55.	1.7	0
22	The interesting case "orphan diseases" double trouble. <i>Annals of Translational Medicine</i> , 2019, 7, S74-S74.	1.7	2
23	Ursodeoxycholyt lysophosphatidylethanolamide negatively regulates TLR-mediated lipopolysaccharide response in human THP-1-derived macrophages. <i>European Journal of Pharmacology</i> , 2018, 825, 63-74.	3.5	3
24	The metabolic capacity of lipid droplet localized acyl-CoA synthetase 3 is not sufficient to support local triglyceride synthesis independent of the endoplasmic reticulum in A431 cells. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2018, 1863, 614-624.	2.4	24
25	Diterpenoid trigonoreidon B isolated from <i>Trigonostemon reidioides</i> alleviates inflammation in models of LPS-stimulated murine macrophages and inflammatory liver injury in mice. <i>Biomedicine and Pharmacotherapy</i> , 2018, 101, 961-971.	5.6	14
26	Pregnancy in Wilson's disease: Management and outcome. <i>Hepatology</i> , 2018, 67, 1261-1269.	7.3	61
27	Ridinilazole "a novel antibiotic for treatment of <i>Clostridium difficile</i> infection. <i>Journal of Thoracic Disease</i> , 2018, 10, 118-120.	1.4	4
28	The Detergent Effect of Mesalazine Interferes with Phosphatidylcholine Binding to Mucin 2. <i>Inflammatory Intestinal Diseases</i> , 2018, 3, 107-115.	1.9	9
29	Nonclassical Interactions of Phosphatidylcholine with Mucin Protect Intestinal Surfaces: A Microinterferometry Study. <i>Langmuir</i> , 2018, 34, 14046-14057.	3.5	9
30	Bivalent Ligand UDCA-LPE Inhibits Pro-Fibrogenic Integrin Signalling by Inducing Lipid Raft-Mediated Internalization. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3254.	4.1	5
31	Survival of Hepatocellular Carcinoma Patients Treated with Sorafenib beyond Progression. <i>Gastrointestinal Tumors</i> , 2018, 5, 38-46.	0.7	8
32	Circulating Phospholipid Patterns in NAFLD Patients Associated with a Combination of Metabolic Risk Factors. <i>Nutrients</i> , 2018, 10, 649.	4.1	60
33	Metallothionein is elevated in liver and duodenum of Atp7b ("") mice. <i>BioMetals</i> , 2018, 31, 617-625.	4.1	10
34	Anti-inflammatory properties of ursodeoxycholyt lysophosphatidylethanolamide in endotoxin-mediated inflammatory liver injury. <i>PLoS ONE</i> , 2018, 13, e0197836.	2.5	9
35	Predictors of functional benefit of hepatitis C therapy in a "real-life" cohort. <i>World Journal of Gastroenterology</i> , 2018, 24, 852-861.	3.3	3
36	Von Willebrand factor and alkaline phosphatase predict retransplantation-free survival after the first liver transplantation. <i>United European Gastroenterology Journal</i> , 2017, 5, 86-93.	3.8	13

#	ARTICLE	IF	CITATIONS
37	Accumulation of phosphatidylcholine on gut mucosal surface is not dominated by electrostatic interactions. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2017, 1859, 959-965.	2.6	18
38	Genetic Mouse Models with Intestinal-Specific Tight Junction Deletion Resemble an Ulcerative Colitis Phenotype. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1247-1257.	1.3	30
39	The overall fatty acid absorption controlled by basolateral chylomicron excretion under regulation of p-JNK1. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2017, 1862, 917-928.	2.4	12
40	Carcinoembryonic Antigen Level in Primary Sclerosing Cholangitis Is Not Influenced by Dominant Strictures or Bacterial Cholangitis. <i>Digestive Diseases and Sciences</i> , 2017, 62, 510-516.	2.3	7
41	Slow ventricular tachycardia presenting with acute liver failure. <i>SAGE Open Medical Case Reports</i> , 2017, 5, 2050313X1771810.	0.3	0
42	Ageing sensitized by iPLA 2β deficiency induces liver fibrosis and intestinal atrophy involving suppression of homeostatic genes and alteration of intestinal lipids and bile acids. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2017, 1862, 1520-1533.	2.4	16
43	Ursodeoxycholy Lysophosphatidylethanolamide Protects Against CD95/FAS-Induced Fulminant Hepatitis. <i>Shock</i> , 2017, 48, 251-259.	2.1	5
44	Treatment efficacy of a probiotic preparation for non-alcoholic steatohepatitis: A pilot trial. <i>Journal of Digestive Diseases</i> , 2017, 18, 698-703.	1.5	70
45	Wilson disease. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2017, 142, 205-209.	1.8	6
46	Novel perspectives on Wilson disease treatment. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2017, 142, 225-230.	1.8	16
47	Phospholipase A 2 of Microbiota as Pathogenetic Determinant to Induce Inflammatory States in Ulcerative Colitis: Therapeutic Implications of Phospholipase A 2 Inhibitors. <i>Inflammatory Intestinal Diseases</i> , 2017, 2, 180-187.	1.9	12
48	Blood Trimethylamine-N-Oxide Originates from Microbiota Mediated Breakdown of Phosphatidylcholine and Absorption from Small Intestine. <i>PLoS ONE</i> , 2017, 12, e0170742.	2.5	40
49	Comparative assessment of clinical rating scales in Wilson's disease. <i>BMC Neurology</i> , 2017, 17, 140.	1.8	28
50	Microbiology and resistance in first episodes of spontaneous bacterial peritonitis: implications for management and prognosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1191-1195.	2.8	51
51	Phosphatidylcholine passes through lateral tight junctions for paracellular transport to the apical side of the polarized intestinal tumor cell-line CaCo2. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2016, 1861, 1161-1169.	2.4	22
52	Control of diabetic hyperglycaemia and insulin resistance through TSC22D4. <i>Nature Communications</i> , 2016, 7, 13267.	12.8	27
53	Wilson disease: Health-related quality of life and risk for depression. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016, 40, 349-356.	1.5	21
54	A common genetic variant of <i>fucosyltransferase 2</i> correlates with serum carcinoembryonic antigen levels and affects cancer screening in patients with primary sclerosing cholangitis. <i>United European Gastroenterology Journal</i> , 2016, 4, 84-91.	3.8	17

#	ARTICLE	IF	CITATIONS
55	iPLA2 ² deficiency attenuates obesity and hepatic steatosis in ob / ob mice through hepatic fatty-acyl phospholipid remodeling. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2016, 1861, 449-461.	2.4	30
56	Concomitant immune-related events in Wilson disease: implications for monitoring chelator therapy. <i>Journal of Inherited Metabolic Disease</i> , 2016, 39, 125-130.	3.6	15
57	Intestinal-borne dermatoses significantly improved by oral application of <i>Escherichia coli</i> Nissle 1917. <i>World Journal of Gastroenterology</i> , 2016, 22, 5415.	3.3	30
58	Outcomes and risk factors for cancer patients undergoing endoscopic intervention of malignant biliary obstruction. <i>BMC Gastroenterology</i> , 2015, 15, 171.	2.0	5
59	Ursodeoxycholy Lysophosphatidylethanolamide modifies aberrant lipid profiles in <i>NAFLD</i> . <i>European Journal of Clinical Investigation</i> , 2015, 45, 925-931.	3.4	14
60	Ursodeoxycholy Lysophosphatidylethanolamide Protects Against Hepatic Ischemia and Reperfusion Injury in Mice. <i>Shock</i> , 2015, 43, 379-386.	2.1	11
61	Palmitate activation by fatty acid transport protein 4 as a model system for hepatocellular apoptosis and steatosis. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2015, 1851, 549-565.	2.4	27
62	Sensitization to autoimmune hepatitis in group VIA calcium-independent phospholipase A2-null mice led to duodenal villous atrophy with apoptosis, goblet cell hyperplasia and leaked bile acids. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2015, 1852, 1646-1657.	3.8	18
63	Inflammation But Not Biliary Obstruction Is Associated With Carbohydrate Antigen 19-9 Levels in Patients With Primary Sclerosing Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2372-2379.	4.4	21
64	Microscopic (collagenous) colitis in a patient with a heart transplant. <i>Endoscopy</i> , 2015, 47, E314-E315.	1.8	1
65	Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center "real-life" cohort. <i>BMC Gastroenterology</i> , 2015, 15, 97.	2.0	19
66	Deficiency of Group VIA Phospholipase A2 (iPLA2 ²) Renders Susceptibility for Chemical-Induced Colitis. <i>Digestive Diseases and Sciences</i> , 2015, 60, 3590-3602.	2.3	10
67	Hepatobiliary malignancies in Wilson disease. <i>Liver International</i> , 2015, 35, 1615-1622.	3.9	78
68	Ursodeoxycholy lysophosphatidylethanolamide inhibits cholestasis- and hypoxia-induced apoptosis by upregulating antiapoptosis proteins. <i>Experimental Biology and Medicine</i> , 2015, 240, 252-260.	2.4	8
69	Deficiency of iPLA2 ² Primes Immune Cells for Proinflammation: Potential Involvement in Age-Related Mesenteric Lymph Node Lymphoma. <i>Cancers</i> , 2015, 7, 2427-2442.	3.7	13
70	Real-life outcome of anti-tumor necrosis factor \pm in the ambulatory treatment of ulcerative colitis. <i>World Journal of Gastroenterology</i> , 2015, 21, 3282-3290.	3.3	20
71	Entzündliche Lebererkrankungen. , 2015, , 303-349.		0
72	Genetisch bedingte Stoffwechselerkrankungen des Gastrointestinaltrakts. , 2015, , 613-629.		0

#	ARTICLE	IF	CITATIONS
73	Oxidative Stress Activates Membrane Ion Channels in Human Biliary Epithelial Cancer Cells (Mz-Cha-1). Anticancer Research, 2015, 35, 5881-8.	1.1	3
74	Plasma membrane phospholipase A ₂ controls hepatocellular fatty acid uptake and is responsive to pharmacological modulation: implications for nonalcoholic steatohepatitis. FASEB Journal, 2014, 28, 3159-3170.	0.5	35
75	Ursodeoxycholyt lysophosphatidylethanolamide attenuates hepatofibrogenesis by impairment of TGF β ² /Smad2/3 signalling. British Journal of Pharmacology, 2014, 171, 5113-5126.	5.4	18
76	Protein mediated fatty acid uptake: Synergy between CD36/FAT-facilitated transport and acyl-CoA synthetase-driven metabolism. Archives of Biochemistry and Biophysics, 2014, 546, 8-18.	3.0	34
77	Clinical considerations for an effective medical therapy in Wilson's disease. Annals of the New York Academy of Sciences, 2014, 1315, 81-85.	3.8	65
78	Differentially localized acyl-CoA synthetase 4 isoenzymes mediate the metabolic channeling of fatty acids towards phosphatidylinositol. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2014, 1841, 227-239.	2.4	102
79	Extracorporeal Life Support and Plasmapheresis in a Case of Severe Polyintoxication. Journal of Emergency Medicine, 2014, 47, 527-531.	0.7	26
80	First Multicenter Study of Modified Release Phosphatidylcholine α -LT-02 in Ulcerative Colitis: A Randomized, Placebo-Controlled Trial in Mesalazine-Refractory Courses. American Journal of Gastroenterology, 2014, 109, 1041-1051.	0.4	94
81	Hepatocyte expression of TRAIL pathway regulators correlates with histopathological and clinical parameters in chronic HCV infection. Pathology Research and Practice, 2014, 210, 83-91.	2.3	9
82	Pharmacodynamic monitoring of nuclear factor of activated T cell-regulated gene expression in liver allograft recipients on immunosuppressive therapy with calcineurin inhibitors in the course of time and correlation with acute rejection episodes â€” a prospective study. Annals of Transplantation, 2014, 19, 32-40.	0.9	25
83	Effects of Increased Von Willebrand Factor Levels on Primary Hemostasis in Thrombocytopenic Patients with Liver Cirrhosis. PLoS ONE, 2014, 9, e112583.	2.5	22
84	Bacteriobilia and fungibilia are associated with outcome in patients with endoscopic treatment of biliary complications after liver transplantation. Endoscopy, 2013, 45, 890-896.	1.8	35
85	Salmonella enterica serovar Minnesota urosepsis in a patient with Crohn's disease in the absence of recent or current gastrointestinal symptoms. Journal of Medical Microbiology, 2013, 62, 1360-1362.	1.8	7
86	Ursodeoxycholyt Lysophosphatidylethanolamide Inhibits Lipoapoptosis by Shifting Fatty Acid Pools toward Monosaturated and Polyunsaturated Fatty Acids in Mouse Hepatocytes. Molecular Pharmacology, 2013, 84, 696-709.	2.3	17
87	Flotillin-2 Expression in the Human Gut: from a Cell Model to Human Tissue in Health and Inflammatory Bowel Diseases. International Journal of Medical Sciences, 2013, 10, 1259-1270.	2.5	4
88	The Diagnosis and Treatment of Minimal Hepatic Encephalopathy. Deutsches Ärztblatt International, 2012, 109, 180-7.	0.9	44
89	Role of myocyte enhancing factor 2B in epithelial myofibroblast transition of human gingival keratinocytes. Experimental Biology and Medicine, 2012, 237, 178-185.	2.4	7
90	Factors modifying phenotypic presentation in Wilson disease: authors' reply. Liver International, 2012, 32, 870-870.	3.9	0

#	ARTICLE	IF	CITATIONS
91	Mucosal Protection by Phosphatidylcholine. Digestive Diseases, 2012, 30, 85-91.	1.9	57
92	Hepatoprotectant Ursodeoxycholy Lysophosphatidylethanolamide Increasing Phosphatidylcholine Levels as a Potential Therapy of Acute Liver Injury. Frontiers in Physiology, 2012, 3, 24.	2.8	14
93	Ursodeoxycholy lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease. Hepatology, 2012, 55, 1369-1378.	7.3	67
94	Iron metabolism and the role of <i>HFE</i> gene polymorphisms in <i>W</i> ilson disease. Liver International, 2012, 32, 165-170.	3.9	38
95	Comparison of different bile acid-phospholipid conjugates in acute hepatitis. European Journal of Clinical Investigation, 2012, 42, 130-138.	3.4	5
96	Evolving Perspectives in Wilson Disease: Diagnosis, Treatment and Monitoring. Current Gastroenterology Reports, 2012, 14, 1-7.	2.5	47
97	Zinc Monotherapy Is Not as Effective as Chelating Agents in Treatment of Wilson Disease. Gastroenterology, 2011, 140, 1189-1198.e1.	1.3	181
98	Gender Influences the Clinical Presentation of Wilson Disease (WD). Gastroenterology, 2011, 140, S-939.	1.3	2
99	The synthetic bile acid-phospholipid conjugate ursodeoxycholy lysophosphatidylethanolamide suppresses TNF α -induced liver injury. Journal of Hepatology, 2011, 54, 674-684.	3.7	40
100	Overexpression of CD36 and Acyl-CoA Synthetases FATP2, FATP4 and ACSL1 Increases Fatty Acid Uptake in Human Hepatoma Cells. International Journal of Medical Sciences, 2011, 8, 599-614.	2.5	115
101	Reduced hydrophobicity of the colonic mucosal surface in ulcerative colitis as a hint at a physicochemical barrier defect. International Journal of Colorectal Disease, 2011, 26, 989-998.	2.2	11
102	Adipocyte-specific Inactivation of Acyl-CoA Synthetase Fatty Acid Transport Protein 4 (Fatp4) in Mice Causes Adipose Hypertrophy and Alterations in Metabolism of Complex Lipids under High Fat Diet. Journal of Biological Chemistry, 2011, 286, 35578-35587.	3.4	44
103	FATP4 contributes as an enzyme to the basal and insulin-mediated fatty acid uptake of C ₂ C ₁₂ muscle cells. American Journal of Physiology - Endocrinology and Metabolism, 2011, 301, E785-E796.	3.5	29
104	Delayed Release Phosphatidylcholine in Chronic-active Ulcerative Colitis. Journal of Clinical Gastroenterology, 2010, 44, e101-e107.	2.2	41
105	Lipid Based Therapy for Ulcerative Colitis-Modulation of Intestinal Mucus Membrane Phospholipids as a Tool to Influence Inflammation. International Journal of Molecular Sciences, 2010, 11, 4149-4164.	4.1	61
106	Phosphatidylcholine (Lecithin) and the Mucus Layer: Evidence of Therapeutic Efficacy in Ulcerative Colitis?. Digestive Diseases, 2010, 28, 490-496.	1.9	46
107	Genetic analysis of <i>BIRC4/XIAP</i> as a putative modifier gene of Wilson disease. Journal of Inherited Metabolic Disease, 2010, 33, 233-240.	3.6	47
108	Phosphatidylcholine as a constituent in the colonic mucosal barrier-Physiological and clinical relevance. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2010, 1801, 983-993.	2.4	73

#	ARTICLE	IF	CITATIONS
109	Delayed release phosphatidylcholine as new therapeutic drug for ulcerative colitis – a review of three clinical trials. Expert Opinion on Investigational Drugs, 2010, 19, 1623-1630.	4.1	21
110	Hepatic Metabolism. , 2010, , 75-102.		2
111	Targeting of acyl-CoA synthetase 3 to lipid droplets. FASEB Journal, 2010, 24, 845.3.	0.5	0
112	FATP4 contributes as an enzyme to the insulin mediated fatty acid uptake of C2C12 muscle cells. FASEB Journal, 2010, 24, 845.1.	0.5	0
113	Bile salt-phospholipid conjugate ursodeoxycholyl lysophosphatidylethanolamide as a hepatoprotective agent. Hepatology, 2009, 50, 143-154.	7.3	41
114	Alterations of phospholipid concentration and species composition of the intestinal mucus barrier in ulcerative colitis: A clue to pathogenesis. Inflammatory Bowel Diseases, 2009, 15, 1705-1720.	1.9	152
115	Transcript levels of different cytokines and chemokines correlate with clinical and endoscopic activity in ulcerative colitis. BMC Gastroenterology, 2009, 9, 13.	2.0	26
116	TNF- α -induced up-regulation of pro-inflammatory cytokines is reduced by phosphatidylcholine in intestinal epithelial cells. BMC Gastroenterology, 2009, 9, 53.	2.0	90
117	Copper-Induced Translocation of the Wilson Disease Protein ATP7B Independent of Murr1/COMMD1 and Rab7. American Journal of Pathology, 2008, 173, 1783-1794.	3.8	32
118	Anti-inflammatory Effects of Phosphatidylcholine. Journal of Biological Chemistry, 2007, 282, 27155-27164.	3.4	236
119	Phosphatidylcholine for Steroid-Refractory Chronic Ulcerative Colitis. Annals of Internal Medicine, 2007, 147, 603.	3.9	84
120	Late-Onset Wilson's Disease. Gastroenterology, 2007, 132, 1294-1298.	1.3	227
121	Diagnostic criteria for acute liver failure due to Wilson disease. World Journal of Gastroenterology, 2007, 13, 1711.	3.3	93
122	Hfe Acts in Hepatocytes To Prevent Hemochromatosis.. Blood, 2007, 110, 703-703.	1.4	1
123	Adipositas und Unterernährung. , 2007, , 436-443.		0
124	Metabolische und genetisch determinierte Lebererkrankungen. , 2007, , 894-900.		0
125	Lentiviral gene transfer ameliorates disease progression in Long-Evans cinnamon rats: An animal model for Wilson disease. Scandinavian Journal of Gastroenterology, 2006, 41, 974-982.	1.5	51
126	Caveolin-1 is required for fatty acid translocase (FAT/CD36) localization and function at the plasma membrane of mouse embryonic fibroblasts. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2006, 1761, 416-423.	2.4	124

#	ARTICLE	IF	CITATIONS
127	Cellular uptake of fatty acids driven by the ER-localized acyl-CoA synthetase FATP4. Journal of Cell Science, 2006, 119, 4678-4688.	2.0	190
128	Metabolische und genetisch determinierte Lebererkrankungen. , 2005, , 813-819.		1
129	FAT/CD36-mediated Long-Chain Fatty Acid Uptake in Adipocytes Requires Plasma Membrane Rafts. Molecular Biology of the Cell, 2005, 16, 24-31.	2.1	167
130	Enzymatic Properties of Purified Murine Fatty Acid Transport Protein 4 and Analysis of Acyl-CoA Synthetase Activities in Tissues from FATP4 Null Mice. Journal of Biological Chemistry, 2005, 280, 11948-11954.	3.4	127
131	Evidence of luminal phosphatidylcholine secretion in rat ileum. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2004, 1682, 63-71.	2.4	36
132	Human enteric glia have the potential to modulate inflammatory processes. Gastroenterology, 2003, 124, A347.	1.3	0
133	Mice with targeted disruption of the fatty acid transport protein 4 (Fatp 4, Slc27a4) gene show features of lethal restrictive dermopathy. Journal of Cell Biology, 2003, 161, 1105-1115.	5.2	173
134	Role of FATP in parenchymal cell fatty acid uptake. Advances in Molecular and Cell Biology, 2003, , 81-87.	0.1	0
135	Stoffwechselerkrankungen und Störungen der Ernährung. , 2003, , 409-506.		0
136	Erkrankungen von Leber, Gallenwegen und Pankreas. , 2003, , 863-954.		0
137	Importance of Copper and Zinc in Alzheimer's Disease and the Biology of Amyloid- β^2 Protein and Amyloid- β^2 Protein Precursor. , 2003, , 245-261.		0
138	Evidence for vesicles that mediate long-chain fatty acid uptake by human microvascular endothelial cells. Journal of Lipid Research, 2002, 43, 2095-2104.	4.2	24
139	Specific interaction of the nonstructural protein NS1 of minute virus of mice (MVM) with [ACCA]2 motifs in the centre of the right-end MVM DNA palindrome induces hairpin-primed viral DNA replication. Journal of General Virology, 2002, 83, 1659-1664.	2.9	10
140	Uptake of long-chain fatty acids in HepG2 cells involves caveolae. Journal of Lipid Research, 2002, 43, 1390-1399.	4.2	95
141	Sensitive and real-time determination of H2O2 release from intact peroxisomes. Biochemical Journal, 2002, 363, 483-491.	3.7	48
142	Mouse fatty acid transport protein 4 (FATP4): Characterization of the gene and functional assessment as a very long chain acyl-CoA synthetase. Gene, 2001, 270, 31-40.	2.2	145
143	A new concept of cellular uptake and intracellular trafficking of long-chain fatty acids. Lipids, 2001, 36, 981-989.	1.7	188
144	Effective infection, apoptotic cell killing and gene transfer of human hepatoma cells but not primary hepatocytes by parvovirus H1 and derived vectors. Cancer Gene Therapy, 2001, 8, 158-167.	4.6	68

#	ARTICLE	IF	CITATIONS
145	Vacuolating Cytotoxin of <i>Helicobacter pylori</i> Induces Apoptosis in the Human Gastric Epithelial Cell Line AGS. Infection and Immunity, 2001, 69, 5080-5087.	2.2	157
146	Sodium, Hydrogen exchange type 1 and bile ductular secretory activity in the guinea pig. Hepatology, 2000, 31, 562-571.	7.3	15
147	Localization of the Wilson's disease protein in human liver. Gastroenterology, 1999, 117, 1380-1385.	1.3	92
148	18F-labeled fluorouracil positron emission tomography and the prognoses of colorectal carcinoma patients with metastases to the liver treated with 5-fluorouracil. , 1998, 83, 245-253.		67
149	Incidence, prevalence, and clinical outcome of hepatitis GB-C virus infection in liver transplant patients. Liver Transplantation, 1998, 4, 28-33.	1.8	5
150	Clinical impact of GB-C virus in haemodialysis patients. Nephrology Dialysis Transplantation, 1998, 13, 93-98.	0.7	14
151	18F-labeled fluorouracil positron emission tomography and the prognoses of colorectal carcinoma patients with metastases to the liver treated with 5-fluorouracil. Cancer, 1998, 83, 245-253.	4.1	2
152	Tumor Necrosis Factor Increases Serum Leptin Levels in Humans. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 4080-4082.	3.6	225
153	Direct Evidence for Catalase as the Predominant H ₂ O ₂ -Removing Enzyme in Human Erythrocytes. Blood, 1997, 90, 4973-4978.	1.4	210
154	Direct Evidence for Catalase as the Predominant H ₂ O ₂ -Removing Enzyme in Human Erythrocytes. Blood, 1997, 90, 4973-4978.	1.4	9
155	Effect of ursodeoxycholic acid on HCV replication in subtyped chronic hepatitis C. Digestive Diseases and Sciences, 1996, 41, 1276-1277.	2.3	4
156	Wilson Disease: Clinical Presentation, Treatment, and Survival. Annals of Internal Medicine, 1991, 115, 720-726.	3.9	250
157	Intestinal absorption of unconjugated dihydroxy bile acids: Non-mediation by the carrier system involved in long chain fatty acid absorption. Lipids, 1990, 25, 11-16.	1.7	13
158	The membrane fatty acid-binding protein is not identical to mitochondrial glutamic oxaloacetic transaminase (mGOT). , 1990, , 191-199.		0
159	Fatty acid uptake by human hepatoma cell lines represents a carrier-mediated uptake process. Biochimica Et Biophysica Acta - Molecular Cell Research, 1989, 1013, 218-222.	4.1	27
160	Transmembrane transport of fatty acids in the heart. , 1989, , 23-29.		2
161	Characteristics of Organic Anion Binding Proteins from Rat Liver Sinusoidal Plasma Membranes. Proceedings in Life Sciences, 1989, , 195-210.	0.5	6
162	Mechanism of Hepatic Fatty Acid Uptake. Proceedings in Life Sciences, 1989, , 211-220.	0.5	1

#	ARTICLE	IF	CITATIONS
163	Role of plasma membrane ligand-binding proteins in the hepatocellular uptake of albumin-bound organic anions. Hepatology, 1987, 7, 165-176.	7.3	116
164	Mechanism of Hepatic Fatty Acid Uptake. , 1987, , 13-22.		0
165	Selective inhibition of long-chain fatty acid uptake in short-term cultured rat hepatocytes by an antibody to the rat liver plasma membrane fatty acid-binding protein. Lipids and Lipid Metabolism, 1986, 877, 191-197.	2.6	58
166	Differing Abnormalities in Estrogen and Androgen and Insulin Metabolism in Idiopathic Hemochromatosis Versus Alcoholic Liver Disease. Seminars in Liver Disease, 1985, 5, 84-93.	3.6	14
167	Survival and Causes of Death in Cirrhotic and in Noncirrhotic Patients with Primary Hemochromatosis. New England Journal of Medicine, 1985, 313, 1256-1262.	27.0	1,054
168	Studies of oleate binding to rat liver plasma membranes. Biochemical and Biophysical Research Communications, 1983, 112, 88-95.	2.1	39